Merck & Co Inc MRK is trading higher Thursday after the company announced better-than-expected third-quarter financial results.
Merck reported quarterly earnings of $1.75 per share, which beat the estimate of $1.55 per share. The company reported quarterly revenue of $13.2 billion, which beat the estimate of $12.33 billion.
Merck expects full-year 2021 adjusted earnings to be in a range of $5.65 to $5.70 per share versus the estimate of $5.77 per share. The company expects full-year 2021 revenue to be in a range of $47.4 billion to $47.9 billion versus the estimate of $48.16 billion.
"Looking ahead, we remain focused on building more momentum, delivering on our mission of saving and improving lives and continuing to expand our portfolio and pipeline for long-term success and sustainable value creation," said Robert Davis, president and CEO of Merck.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer and infections.
Related Link: Merck's Q3 Earnings Beat Street View, Revises FY21 Outlook Below Consensus
MRK Price Action: Merck is making new 52-week highs during Thursday's session.
The stock was up 4.98% at $85.60 at time of publication.
Photo: courtesy of Merck.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.